N6F11

CAS No. 851398-76-0

N6F11( —— )

Catalog No. M37095 CAS No. 851398-76-0

N6F11 is a novel, selective and potent inducer of ferroptosis with anticancer and antitumour activity that promotes GPX4 degradation by binding to TRIM25 in cancer cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 459 In Stock
10MG 657 In Stock
25MG 1026 In Stock
50MG 1386 In Stock
100MG 1832 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    N6F11
  • Note
    Research use only, not for human use.
  • Brief Description
    N6F11 is a novel, selective and potent inducer of ferroptosis with anticancer and antitumour activity that promotes GPX4 degradation by binding to TRIM25 in cancer cells.
  • Description
    N6F11 is a novel, selective and potent inducer of ferroptosis with anticancer and antitumour activity that promotes GPX4 degradation by binding to TRIM25 in cancer cells.N6F11 can be used to study pancreatic cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    GPX
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    851398-76-0
  • Formula Weight
    311.19
  • Molecular Formula
    C13H8Cl2N2OS
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ClCC1=NC2=C(SC(=C2)C2=CC=C(Cl)C=C2)C(=O)N1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • PF-06952229

    PF-06952229 is an selective and orally active inhibitor of TGFbR1.

  • Tryptamine hydrochlo...

    Tryptamine hydrochloride is a useful organic compound for research related to life sciences.

  • EZH2-IN-2

    EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC50 of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activity.